Related Experiment Videos
[Anticoagulation in thrombolytic therapy: importance and future perspectives]
1I. Medizinische Klinik, Fakultät Klinische Medizin Mannheim der Universität Heidelberg.
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|June 1, 1993
Summary
This review covers direct and indirect anticoagulants, detailing their use alongside thrombolysis for deep vein thrombosis, pulmonary embolism, and myocardial infarction. It highlights the benefits of heparin in myocardial infarction treatment.
Area of Science:
- Pharmacology
- Hematology
- Cardiology
Context:
- Anticoagulants are crucial in managing thrombotic events.
- Thrombolytic therapy is a standard treatment for deep vein thrombosis, pulmonary embolism, and myocardial infarction.
- Understanding anticoagulant mechanisms and indications is vital for effective treatment.
Purpose:
- To review the mechanisms of action for direct and indirect anticoagulants.
- To outline current and potential indications for anticoagulants in thrombolytic therapy.
- To discuss novel antithrombotic agents and their role in cardiovascular medicine.
Summary:
- The overview details the action of direct and indirect anticoagulants.
- It examines anticoagulant use in thrombolysis for deep vein thrombosis, pulmonary embolism, and myocardial infarction.
- New antithrombotics, including dermatan sulfate, hirudin, synthetic thrombin inhibitors, activated protein C, and glycoprotein IIb/IIIa inhibitors, are reviewed.
- Studies confirm the benefit of concurrent heparin use during thrombolytic treatment of myocardial infarction.
Impact:
- Provides a comprehensive guide to anticoagulant therapy in thrombotic conditions.
- Informs clinical practice regarding the use of established and novel antithrombotics.
- Supports evidence-based decision-making in the management of thromboembolic diseases.